{"organizations": [], "uuid": "3fb9419a9487a2f94bbdc790604e639ee4e59c5d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/08/20/elililly-brief-idUSWNAB081DX20150820", "country": "US", "title": "CORRECTED-BRIEF- Eli Lilly and Co says EMPA-REG OUTCOME met its primary endpoint", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "CORRECTED-BRIEF- Eli Lilly and Co says EMPA-REG OUTCOME met its primary endpoint | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-08-20T16:14:00.000+03:00", "replies_count": 0, "uuid": "3fb9419a9487a2f94bbdc790604e639ee4e59c5d"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/08/20/elililly-brief-idUSWNAB081DX20150820", "ord_in_thread": 0, "title": "CORRECTED-BRIEF- Eli Lilly and Co says EMPA-REG OUTCOME met its primary endpoint", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "(Corrects source to 'Eli Lilly and Co' from 'Jardiance')\nAug 20 (Reuters) - Eli Lilly and Co : * Jardiance demonstrated cardiovascular (cv) risk reduction in people with type 2 diabetes at high risk for cv events * Says empa-reg outcome met its primary endpoint * Says empa-reg outcome demonstrated superiority of jardiance, when added to standard of care, in cv risk reduction * Source text for Eikon * Further company coverage", "external_links": [], "published": "2015-08-20T16:14:00.000+03:00", "crawled": "2015-08-20T15:22:39.679+03:00", "highlightTitle": ""}